Abstract Background: HER2 (human epidermal growth factor receptor 2) overexpression is a pivotal biomarker for breast cancer prognosis and targeted therapy selection. Conventional assessment requires immunohistochemistry (IHC) and/or in situ hybridization (ISH), which are costly, time-consuming, and constrained by limited tissue and resource availability. In contrast, hematoxylin-and-eosin (H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5470.
Su et al. (Fri,) studied this question.